Google
×
Sep 3, 2019 · With placebo, the incidence of death by respective vascular categories was 3.5%, 10.0%, and 21.8%; the absolute risk reduction with alirocumab ...
Overall in the ODYSSEY OUTCOMES trial, the incidence of MACE in the placebo and alirocumab groups was 11.1% and 9.5%, respectively, with a corresponding ARR of ...
Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary heart disease death, ...
In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death.
Jan 13, 2020 · Original Investigation: Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. Letters ...
Vascular reactivity to mental stress is associated with poor cardiovascular disease outcomes in females following acute coronary syndrome. · Risk Factors for ...
In brief,. ODYSSEY OUTCOMES was a multicenter, double- blind, placebo-controlled trial in 18,924 patients at least 40 years of age who provided written informed.
May 16, 2023 · The ODYSSEY OUTCOMES trial showed that use of alirocumab, taken every other week, significantly reduces ischemic events, including all-cause mortality and MI.
Missing: Polyvascular | Show results with:Polyvascular
The ODYSSEY OUTCOMES trial compared alirocumab with placebo, beginning 1 to 12 months after ACS with median 2.8-year follow-up. The primary MACE outcome ...
People also ask
Sep 3, 2019 · METHODS: Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary ...